10 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia (R/R AML), conducted at Israel’s Sheba…
5 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia (R/R AML), conducted at Israel’s Sheba…
Race Oncology Limited is pleased to announce that Professor Borje S. Andersson has agreed to join Race as Chief Medical Officer and Executive Director. Under this role, Prof. Andersson will be responsible for progressing Race’s clinical development plans for Bisantrene.…
Race Oncology is pleased to announce that it has appointed the clinical and regulatory strategy advisor, CCS Associates (CCSA, California, USA) to advise on development options for Bisantrene as an inhibitor of the Fat mass and obesity-associated protein (FTO). Recent…
Our executive leaders discuss the benefits of a shared leadership model and the experience they each bring to Race Oncology.
1 September 2020 – Race Oncology Limited (ASX: RAC) is pleased to announce that it has expanded its executive team with the appointment of Mr Phil Lynch as Chief Executive Officer and Managing Director. Effective immediately, Mr Lynch will share…
Dear Shareholders It is my pleasure to formally open the annual report to Race Oncology Shareholders for the period ended 30 June 2020. It’s been a highly successful year as regards progress in reframing the opportunity for Bisantrene in Acute…
Race Oncology is please update our shareholders on the clinical progress of bisantrene. This talk was presented by Race Oncology’s CSO Dr Daniel Tillett at the IRD Invest virtual conference on the 29th July 2019.
22 July 2020 – Race Oncology Limited (ASX:RAC) is pleased to announce that Dr Daniel Tillett will present at the IRD Invest virtual investor conference on Wednesday, 29 July 2020 at 12.00 pm AEST. Dr Tillett will provide an update on the recent…
On 16 July 2020, Race was pleased to report results of the investigator led Phase II trial of bisantrene for relapsed or refractory Acute Myleoid Leukaemia. This post summarises the highlights and provides access to key resources related to the…
